Ming-Hsin Yeh
Overview
Explore the profile of Ming-Hsin Yeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liu H, Cheng-Chung Wei J, Yip H, Yeh M
Front Oncol
. 2021 Oct;
11:757626.
PMID: 34707998
Background: Insomnia, depressive disorders, and to a more general view, mood disorders are raising people's concerns and causing disability of life. Herein, we try to seek the association of such...
12.
He Y, Yeh M, Chen H, Wang T, Wong R, Wei Y, et al.
Mol Ther Nucleic Acids
. 2021 Sep;
25:536-553.
PMID: 34589276
Mutant p53 (mutp53) commonly loses its DNA binding affinity to p53 response elements (p53REs) and fails to induce apoptosis fully. However, the p53 mutation does not predict chemoresistance in all...
13.
Li Y, Chiou J, Lin C, Cheng-Chung Wei J, Yeh M
Medicine (Baltimore)
. 2021 Jun;
100(19):e25637.
PMID: 34106591
Breast cancer has the highest incidence of cancer among women in Taiwan, and air pollutants have been documented to have multiple adverse effects on human health. There is no relevant...
14.
Huang C, Cheng-Chung Wei J, Chien T, Kuo C, Lin S, Su Y, et al.
Endocr Pract
. 2021 Mar;
27(4):298-305.
PMID: 33779560
Objectives: The results of studies investigating the relationship between breast cancer and hypothyroidism vary greatly from study to study. In this study, we analyzed a large and reliable, population-based database...
15.
Yeh M, Tzeng Y, Fu T, You J, Chang H, Ger L, et al.
Anticancer Res
. 2018 Aug;
38(8):4593-4605.
PMID: 30061226
Background/aim: Breast cancer is a common type of cancer in women, and metastasis frequently leads to therapy failure. Using next-generation sequencing (NGS), we aspired to identify the optimal differentially expressed...
16.
Chang H, Tseng Y, Chen Y, Shu C, Lin M, Liou H, et al.
Surg Oncol
. 2018 Jun;
27(2):314-320.
PMID: 29937187
Background: High Snail expression is known as a poor prognostic factor in breast cancer. However, its prognostic impact for breast cancer with different molecular subtypes is still controversial. Methods: Snail...
17.
Lai H, Liu L, Ouyang F, Yao C, Jan H, Chang Y, et al.
PLoS One
. 2017 Nov;
12(11):e0185876.
PMID: 29095832
Background: In this multi-center study, we report the patient selection criteria for and preliminary oncologic outcomes associated with intraoperative radiotherapy (IORT) delivered by the Xoft Axxent® eBx® system for early-stage...
18.
Chen C, Hsia T, Yeh M, Chen T, Chen Y, Chen J, et al.
Mol Oncol
. 2017 Jun;
11(9):1273-1287.
PMID: 28632938
Targeting the MEK/ERK pathway has been viewed as a promising strategy for cancer therapy. However, MEK inhibition leads to the compensatory PI3K/AKT activation and thus contributes to the desensitization of...
19.
Lin P, Kuo W, Huang A, Lu Y, Lin C, Kuo S, et al.
Oncotarget
. 2016 Jan;
7(7):8310-20.
PMID: 26824983
Since BRCA mutations are only responsible for 10-20% of cases of breast cancer in patients with early-onset or a family history and since next-generation sequencing technology allows the simultaneous sequencing...
20.
Hsiao Y, Yeh M, Chen Y, Liu J, Tang C, Huang W
Oncotarget
. 2015 Oct;
6(35):37965-78.
PMID: 26513016
Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor (TKI), has been approved for HER2-positive breast cancer patients. Nevertheless, its inhibitory effect on EGFR did not...